| Name | Title | Contact Details |
|---|
BiOptix Diagnostics is a privately held firm based in Boulder, Colorado, with leading investments from Boulder Ventures, Remeditex and Rusnano. BiOptix has developed a new class of analytical biosensor instrumentation utilizing a patented high-throughput label-free technology known as ESPR – Enhanced Surface Plasmon Resonance. BiOptix instrumentation allows researchers to study label-free protein-protein and protein-small molecule interaction—with high sensitivity and high throughput. Applications include: Protein-small molecule interactions, protein-protein kinetics, antibody affinities and epitope mapping, oligosaccharide characterization, nucleic acid (DNA-DNA or DNA-RNA) hybridization and biomolecule concentration measurements.
Cue Health is a health technology company that develops and manufactures portable, compact, connected medical diagnostic products that help people, organizations, and communities protect human health. Headquartered in San Diego, California, our mission is to empower healthcare providers and organizations by increasing their access to rapid, accurate, actionable health data in real-time. We have built a culture that is dynamic, innovative, and results-oriented. We seek driven and talented individuals to join our multi-disciplinary engineering, regulatory, clinical, operations, production, and testing teams. If you`re ready to help us reinvent the future of healthcare, reach out to us today.
Omeros Corporation is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.
Freeline is a clinical-stage, fully integrated, next generation, systemic AAV-based gene therapy company with the ambition of transforming the lives of patients suffering from inherited systemic debilitating diseases. We are headquartered in the UK and we also have operations in Germany and the US. Freeline was founded in 2015 and builds upon the pioneering work by our Clinical and Scientific Advisor and Director, Professor Amit Nathwani, Professor of Haematology at UCL. With our liver-based investigational gene therapy technology, we aim to improve the lives of people with chronic systemic diseases and realise the potential of gene therapy treatments.
MANA was founded in November 2018, based on the research and human proof-of-concept clinical trials conducted by Dr. Catherine Bollard and her team at Children`s National Hospital (CNH) in Washington, D.C., along with colleagues at Johns Hopkins Medical Center.